• About us
• Contact

Advertisement

Organisation › Details

Probiodrug (Group)

Headquartered in Halle, Germany, Probiodrug AG (Euronext Amsterdam: PBD) is a biopharmaceutical company focused on the development of new therapeutic products for the treatment of Alzheimer’s disease. Founded in 1997, the company successfully developed a novel therapeutic concept for diabetes – the DP4 inhibitors – which provided the basis for a novel class of antidiabetics – the gliptins. Its core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes involved in the modification of proteins and peptides, which play a central role in pathological conditions. Today Probiodrug’s aim is to become a leading company in the development of Alzheimer’s disease treatments and to thereby provide a better life for Alzheimer’s disease patients. It has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to fight Alzheimer’s disease. The Company has medical use and composition of matter patents related to the inhibition of Glutaminyl Cyclase (QC) and anti-pGlu-Abeta- specific monoclonal antibodies, providing it, in the Company’s view, with a leading position in this field of research. *

 

	Start	1997-06-01 established
	End	2019-06-11 renamed
	Group	Vivoryon (Group)
	Today	Vivoryon (Group)
	Successor	Vivoryon (Group)
	Industry	drug development technology
	Industry 2	QC inhibitor (glutam(in)yl cyclase inhibitor)
	Person	Dauer, Ulrich (Probiodrug 201805– CEO before Omeicos + Activaero + 4SC + Tripos)
	Person 2	Schäffer, Michael (Probiodrug 201810– CBO joined 201808 as EVP Business + Strategy before Crelux + Sireen)
	Region	Halle (Saale)
	Country	Germany
	Street	22 Weinbergweg
	City	06120 Halle (Saale)
	Tel	+49-345-55599-00
		Address record changed: 2020-12-02
Basic data	Employees	B: 11 to 50 (2016-12-31)
	Currency	EUR
	Annual sales	44,000 (operating income (2015) 2015-12-31)
	Profit	-13,891,000 (2016-12-31)
	Cash	9,300,000 (2018-03-31)
		* Document for »About Section«:
		Record changed: 2023-12-30

Advertisement

More documents for Vivoryon (Group)

• [1] Vivoryon Therapeutics N.V.. (6/29/21). "Press Release: Vivoryon Therapeutics and Simcere Announce Strategic Regional Licensing Partnership to Develop and Commercialize N3pE Amyloid-targeting Medicines to Treat Alzheimer's Disease in Greater China". Halle...
• [2] Vivoryon Therapeutics AG. (1/14/20). "Press Release: Vivoryon Therapeutics and Nordic Bioscience Enter Research and Development Collaboration". Halle (Saale) & Herlev....
• [3] Vivoryon Therapeutics AG. (10/8/19). "Press Release: Vivoryon Therapeutics AG Launches Rights Offering to Fund its Phase 2b Clinical Development Program in Alzheimer’s Disease with Strong Commitments [Not for US, et al.]". Halle (Saale)....
• [4] Vivoryon Therapeutics AG. (8/29/19). "Press Release: Vivoryon Therapeutics Reports Financial Results for H1 2019 and Corporate Update". Halle (Saale)....
• [5] MorphoSys AG. (7/8/19). "Press Release: MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule Inhibitors of CD47-SIRP alpha Signaling in Immuno-Oncology". Planegg & Halle (Saale)....
• [6] Probiodrug AG. (6/12/19). "Press Release: Probiodrug AG Becomes Vivoryon Therapeutics AG". Halle (Saale)....
• [7] Probiodrug AG. (4/9/19). "Press Release: Probiodrug Raises EUR 8.2 Million from Investors in Successful Private Placement of New Shares [NOT FOR PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA]". Halle (Saale)....
• [8] Probiodrug AG. (4/4/19). "Press Release: Probiodrug AG Has Mandated Oddo Seydler Bank AG as Designated Sponsor. The Shares Are Trading on XETRA, the Electronic Trading Platform of Deutsche Börse". Halle (Saale)....
• [9] Probiodrug AG. (3/28/19). "Press Release: Probiodrug Reports Full Year 2018 Financial Results". Halle (Saale)....
• [10] Probiodrug AG. (10/5/18). "Press Release: Probiodrug Reports Management Changes". Halle (Saale)....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.